This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cellceutix Cancer Drug Kevetrin™ Shows No Genotoxicity In Study

BEVERLY, Mass., March 2, 2011 /PRNewswire/ -- Cellceutix Corporation (Pink Sheets: CTIX) today announced that it has received more data on Kevetrin™, the Company's flagship compound for the treatment of cancers. Analysis of the latest research shows Kevetrin™ is non-genotoxic, contrary to the majority of currently available chemotherapeutic drugs.  Genotoxic drugs affect nucleic acids and alter their function. These drugs may directly bind with DNA or may indirectly lead to DNA damage by affecting enzymes involved in DNA replication.  A DNA damaging drug results in rapid phosphorylation of H2A.X at Ser 139 by PI3K-like kinases.  Kevetrin™ did not induce phosphorylation of H2A.X protein; whereas, other chemotherapy drugs, such as Adriamycin, did induce the phosphorylation of H2A.X as shown by Western blot assay.  

Research data announced earlier this week showed that Kevetrin™ reactivates p53, a key protein which plays a critical role in mediating cellular stress responses such as that brought about by DNA-damage. It is therefore vital in regulating a vast array of proteins involved in cell cycle progression, DNA repair, and apoptosis.

Dr. Krishna Menon, Chief Scientific Officer at Cellceutix, commented, "This is another major breakthrough for Kevetrin. p53 activation is considered among the critical molecular events for cancer therapy. The fact that Kevetrin™ reactivated p53 and resulted in tumor suppression in animals with drug resistant cancers was a milestone in oncology on its own, but with Kevetrin™ now proven to be non-genotoxic, we believe this has set the compound at the forefront of developmental cancer therapies."  "

Cellceutix is completing formulation production, scheduled for early March 2011, which would produce Kevetrin™ in the dosage form for planned clinical trials. The Company plans to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration in May 2011 with human trials to begin thereafter.

About Cellceutix

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,572.73 -25.47 -0.14%
S&P 500 2,098.50 +0.46 0.02%
NASDAQ 5,113.5530 -1.8290 -0.04%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs